Advances in Food Technology and Nutritional Sciences

Open journal

ISSN 2377-8350

Comparison of Hispanics to Caucasians in Metabolic Evaluation of Nephrolithiasis

Julie M. Riley, Jessica Ming, Frances Alba and Michael S. Davis*

Received: July 26th, 2018; Revised: October 9th, 2018; Accepted: October 10th, 2018; Published: October 23rd, 2018

INTRODUCTION

The Hispanic population is the largest minority group in the United States and constitutes 17% of the population.1 Projections show that by 2060, Hispanics will make up 31% of the US population.1 Little is known regarding Hispanic-Americans in regards to the metabolic risk of stones and how this compares to the Caucasian-American population, which is traditionally the largest group of stone formers.2,3,4

Our Institution is located within a state where Hispanics are the majority and that has the highest percentage of Hispanics in the country at 47.3%.1 This allows for a unique comparison of Hispanics to Caucasians within one geographic region.

MATERIALS AND METHODS

After institutional IRB approval, a retrospective review was performed at our single tertiary care center. All patients diagnosed with kidney stones who underwent a 24 hour urine stone risk analysis at our institution from 2008-2013 were evaluated. All 24 hour stone risk urine tests were performed by Litholink. Pediatric patients (age <18-years-old) were excluded from analysis as this population has a greater risk of underlying metabolic disease.

Patients were divided into 2 groups based on self-reported ethnicity. Group A included Caucasian patients and group B included Hispanic patients. Other racial/ethnic groups and those who did not designate were excluded. In addition to the urinary stone risk evaluation, stone composition, serum metabolic evaluations, past medical history, patient demographics and body mass index (BMI) were evaluated. The two groups were compared with each other to determine any differences between ethnicities.

RESULTS

A total of 224 patients with 370 urine studies were identified. Fifteen patients with 21 urine studies were excluded because their race/ethnicity was not Caucasian or Hispanic or they did not selfidentify a race/ethnic group. This left 208 patients with 349 urine studies including 122 Caucasians (Group A) and 87 Hispanics (Group B) with 206 and 143 urine studies, respectively.

Group B was significantly younger with an average age of 45.6 (18-78) compared to 50.3 (19-74) in Group A (p=0.02). BMI was not statistically different (p=0.4) between the Group A and Group B (28.3 vs. 29.1, respectively). There were equal numbers of men and women in Group A, yet proportionately more women in Group B (64.4%). Equal percentage of patients within each group had family history (defined as 1st or 2nd degree relatives) of stones (42.6% in Group A and 41.4% in Group B). There were slightly more patients with hypertension in Group A at 31.1% compared to 26.4% in Group B but equal number of diabetics (21.3% for Group A vs. 23.0% in Group B). Table 1 demonstrates the patient demographics of each group.

 

Table 1. Patient Demographics
Group A (Caucasians) Group B (Hispanics) p value
Number 122 87
Number of 24 hour collections 206 143
Age (range) 50.3±14.06 (19-74) 45.6±15.12 (18-78) 0.022
Gender (M:F) 61:61 31:56
BMI 28.34±6.869 29.13±6.584 0.412
Positive Family history 52 (42.6%) 36 (41.4%)
Presence of hypertension 38 (31.1%) 23 (26.4%)
Presence of diabetes mellitus 26 (21.3%) 20 (23.0%)

 

When comparing the two groups for all tests completed, several 24 hour urine parameters were significantly different. Table 2 shows the urinary parameter measurements for each group. Group A had a higher mean urine volume of 2.24 liters compared to 2.21 liters in Group B (p=0.006). Group A had significantly higher urinary oxalate, potassium, phosphorus, sulfate, urine urea nitrogen and 24 hour creatinine compared to Group B. Group A had lower urinary citrate, supersaturation of calcium phosphate and magnesium levels. Remaining urinary parameters were not significantly different.

 

Table 2. Comparison of all 24 hour Urine Parameters
Group A Group B p value (*=significance)
Volume (Liters) 2.24±1.065 1.95±0.886 0.0062*
SS CaOx 6.48±3.254 6.78±3.920 0.456
Calcium (mg/day) 219.84±120.653 217.93±120.409 0.884
Oxalate (mg/day) 39.69±16.590 34.14±13.789 0.0008*
Citrate (mg/day) 586.58±386.808 512.75±307.483 0.0485*
SS CaP 1.15±0.896 1.46±1.210 0.0091*
pH 6.20±0.666 6.27±0.534 0.299
SS UA 0.78±0.837 0.68±0.798 0.267
Uric acid (g/day) 0.61±0.195 0.61±0.219 0.909
Sodium (mmol/day) 172.30±72.313 182.22±82.307 0.246
Potassium (mmol/day) 65.63±32.537 53.77±23.076 0.0001*
Magnesium (mg/day) 101.74±48.342 90.61±40.936 0.0220*
Phosphorus (g/day) 0.92±0.337 0.79±0.343 0.0004*
Ammonium (mmol/day) 31.62±19.051 29.06±12.424 0.134
Chloride (mmol/day) 164.44±68.205 168.04±73.774 0.647
Sulfate (mEq/day) 38.82±15.179 34.98±14.576 0.0185*
Urea Nitrogen (g/day) 10.73±3.645 9.55±3.566 0.0029*
SS CaOx=supersaturation of calcium oxalate, SS CaP–supersaturation of calcium phosphate, SS UA=supersaturation of uric acid

 

Further analysis was done to evaluate only the first collection, taken prior to any dietary or medical therapy was commenced. Group A remained significantly higher in urinary oxalate, potassium, magnesium, phosphorus, ammonium and 24 hour creatinine when compared to Group B. Group B continued to have significantly higher supersaturation of calcium phosphate. The urine volume was not significantly different between the two groups. Table 3 lists the urinary parameters of the first urine collection.

 

Table 3. Comparison of First Urinary Collection
 

Group A

Group B

p value (*=significance)

Volume (Liters)

2.08±1.061

1.87±0.889

0.107

SS CaOx

6.82±3.470

6.71±3.608

0.818

Calcium (mg/day)

217.45±135.288

202.75±109.187

0.387

Oxalate (mg/day)

39.08±16.917

32.17±14.061

0.0035*

Citrate (mg/day)

559.66±334.364

501.45±303.009

0.191

SS CaP

1.11±0.937

1.46±1.278

0.034*

pH

6.10±0.647

6.20±0.510

0.219

SS UA

0.94±0.925

0.76±0.876

0.149

Uric acid (g/day)

0.60±0.181

0.60±0.223

0.868

Sodium (mmol/day)

169.92±76.040

178.28±83.894

0.462

Potassium (mmol/day)

60.19±28.718

50.21±22.011

0.0051*

Magnesium (mg/day)

100.16±51.188

83.30±34.143

0.0050*

Phosphorus (g/day)

0.92±0.337

0.79±0.331

0.0045*

Ammonium (mmol/day)

33.01±20.325

28.05±12.405

0.031*

Chloride (mmol/day)

162.09±70.827

163.20±75.774

0.915

Sulfate (mEq/day)

36.69±14.483

34.01±15.029

0.202

Urea Nitrogen (g/day)

10.45±3.677

9.15±3.586

0.011*

SS CaOx=supersaturation of calcium oxalate, SS CaP–supersaturation of calcium phosphate, SS UA=supersaturation of uric acid

 

Of the 208 patients, 195 (93.7%) had a basic metabolic panel (BMP). There were 111 (90.1%) patients in Group A and 84 (96.6%) patients in Group B who completed a BMP. Serum potassium was higher in Group A (4.15) compared to Group B (4.02). Twenty-eight patients in Group B (32%) had a PTH level and on average the level was higher compared to the 32 patients (26%) in Group A (69.7 vs. 42.6, respectively, p=0.048). Table 4 shows the serum results for the two groups. The remaining serum levels were not significantly different between the two groups.

 

Table 4. Comparison of Serum Results
Group A Group B p value
Sodium 139.51±2.586 139.63±2.610 0.775
Potassium 4.15±0.392 4.02±0.394 0.022*
Chloride 105.23±3.246 105.76±3.535 0.279
Bicarbonate 24.68±2.848 24.02±3.065 0.126
Blood urea Nitroge 15.84±5.800 14.83±6.201 0.253
Creatinine 1.01±0.425 1.81±8.027 0.367
Calcium 9.24±1.038 9.26±0.631 0.855
Magnesium 2.00±0.349 1.91±0.232 0.067
Parathyroid hormone 42.63±28.625 69.74±63.400 0.0486*
Uric acid 5.81±2.209 5.09±1.388 0.202
Vitamin D 25(OH) 29.39±14.411 25.27±14.758 0.286

 

Stone analysis was collected on 117 patients overall. A stone was classified as the predominant stone type if there was more than 80% of that compound present. It was classified as mixed composition if there was less than 80% predominant compound. Stone analysis was performed in 71 (58.2%) of the patients in Group A. Of these 71 patients, 41 (57.7%) had calcium oxalate, 4 (5.6%) had calcium phosphate, 4 (5.6%) had uric acid, 3 (4.2%) had cysteine, 17 (23.9%) had mixed stones. There were no struvite stones present. Stone analysis was performed in 46 (52.3%) of the patients in Group B. Of these 46 patients, 18 (39.1%) had calcium oxalate, 12 (26.1%) had calcium phosphate, 3 (6.5%) had uric acid and 12 (26.1%) had mixed stones. There were no struvite or cysteine stones present. Table 5 shows the stone analysis data.

 

Table 5. Stone Analysis by Group
Group A (71 patients) Group B (46 patients)
Calcium Oxalate 41 (57.7%) 18 (39.1%)
Calcium Phosphate 4 (5.6%) 12 (26.1%)
Uric Acid 4 (5.6%) 3 (6.5%)
Cysteine 3 (4.2%) 0
Struvite 0 0
Mixed 17 (23.9%) 12 (26.1%)

 

DISCUSSION

To the best of our knowledge, we report the first direct comparison in the literature of metabolic evaluation for urolithiasis between Hispanic and Caucasian populations. Our institution is located within a state with nearly equal Hispanic and Caucasian populations. Our unique demographic allowed us to evaluate differences between these two groups who are exposed to the same environment and relatively similar diets.

The analysis showed that Caucasians are more likely to have higher oxalate levels than Hispanics. However, neither group demonstrated overall hyperoxaluria (>40 mg/day) on average. Yet certainly it is known that higher urinary oxalate is associated with increased stone formation.5 Higher oxalate levels may be a more significant cause of stone formation in Caucasians and therefore should be a focus point when counseling and evaluating these patients.

In the Hispanic population, there is a significantly higher urinary supersaturation of calcium phosphate compared to the Caucasian population. The pH was not significantly higher and there does not appear to be an increased risk of renal tubular acidosis. Interestingly, Hispanics did have a higher PTH level than Caucasians. Other studies have also reported this finding, however, its association with risk for stone disease is unclear.6,7 There was certainly a higher proportion of female Hispanic patients which may also explain the increased urinary supersaturation of calcium phosphate. It remains unclear at this time how this affects the overall metabolic evaluation in the Hispanic population but we feel this certainly warrants further study and evaluation.

The observed urinary parameter differences seem to correlate with stone type. The higher rate of calcium oxalate stone formation in Group A may be related to the increased urinary oxalate secretion in this group. In addition, Group B did have a higher rate of calcium phosphate stones with the corresponding increased supersaturation of calcium phosphate in the urine. Certainly this study is not designed to evaluate the cause of stone type among these two groups. Yet-further studies are warranted to determine if there is any relationship between the metabolic parameters and stone type, as well as differences in the causes of stone formation between groups.

While we have shown several differences between our two groups, several limitations exist. This is a retrospective review of data which certainly allows for bias to exist. We compared only those patients that actually completed a metabolic evaluation at our institution. There were many patients with stone disease that were seen and treated for urolithiasis but simply did not complete the workup or for whom work up was not recommended. This may explain why we have an over-representation of females in our groups when considering urolithiasis is a male dominated disease historically.3 Because the study was retrospective in nature and took all patients that completed a 24 hour urine study, unfortunately a gender discrepancy was introduced. Interestingly, however, Dell’era et al. reported in a single institution study, a 1:1 ratio male to female presentation of symptomatic upper tract stones in a Hispanic population.8 It is unclear if there is truly a gender disparity in stone disease within the Hispanic population in our state, or if the observed male to female ratio simply represents a bias error.

Mente et al performed an analysis of multi-ethnic calcium nephrolithiasis formers compared to Caucasians.9 This study included a very small number of patients from Latin America (34, 3% of the study) which were compared to a European control group. The findings demonstrated an increased risk of calcium stones among those from Latin America but there was little ability to interpret underlying causes for this difference. Our study is not designed to determine if the Hispanic population has an increased overall risk of kidney stones, and certainly further population based studies are warranted.

All of our patients completed at least one 24 hour urine test. While some literature supports two 24 hour urine testing initially, other significant data suggests that one is sufficient.10,11 Our patients had poor compliance overall with follow up metabolic testing. Only 37.9% (45) of the patients in Group A completed subsequent 24 hour urine tests. Of the patients in Group B, 40.2% (35) completed repeat 24 hour urine testing. Given the small followup numbers, we determined that further analysis of a difference in repeat testing may not be valid. In the future however, with the addition of more patients this may be something to investigate.

While we have shown that there are differences in urinary parameters between the two groups, we do not know how this effects overall stone formation. Given the very poor compliance of our patient population it was not possible to evaluate for subsequent stone formation within the study time frame.

LIMITATIONS

This is a retrospective review of all patients completing a 24 hour urine study and this certainly introduces selection bias. We do not know how many patients did not complete the metabolic evaluation and therefore this could change the overall results. The groups are not matched and there is a significantly higher amount of women in the Hispanic group. This may explain the differences in the urinary parameters. However, this may also be a difference between the ethnic groups. Dall’era et al demonstrated that there was a 1:1 presentation of male to female stone patients in the Hispanic population in contrast to 2.5:1 male:female ratio in Caucasians.8 Further studies are needed to determine if there is a difference in gender ratio in stone disease in the Hispanic population. In addition, a case matches study may be useful to understand any difference between Caucasians and Hispanics in regards to urinary parameters. Our study, simply highlights that there appears to be a difference in the two groups and additional studies are warranted.

CONCLUSION

Our study suggests that there is a metabolic difference between Caucasian and Hispanic populations. Caucasians show an increased risk of stone formation due to increased oxalate excretion with subsequent higher rates of calcium oxalate stone formation. Hispanics show an increased risk of stone formation due to decreased urinary volume as well as increased supersaturation of calcium phosphate with associated higher rates of calcium phosphate stone formation. Further studies are needed to determine if this is applicable to a wider geographic region, and if this is applicable to all stone formers. This information may be useful for more generalized dietary recommendations pertinent to these two population groups.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

DISCLOSURE

No competing financial interests exist.

1. S. Census Bureau (2010): State and U.S. quickfacts: New Mexico. http://quickfacts.census.gov. Retrieved Feb 27 2015.

2. Maloney ME. Springhart WP, Ekeruo WO, Young MD, Enemchukwu CU, Preminger GM. Ethnic backgrounds has minimal impact on the etiology of nephrolithiasis. J Urol. 2005; 173(6): 2001-2004. doi: 10.1097/01.ju.0000159076.70638.1e

3. Scales CD, Smith AC, Hanley JM, Saigal CS. Urologic diseases in America Project. Urologic diseases in america project. Prevalence of kidney stones in the united states. Eur Urol. 2012; 62(1): 160-165. doi: 10.1016/j.eururo.2012.03.052

4. Stamatelou KK, Frances ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the united states: 1976-1994. Kidney Int. 2003; 63(5): 1817-1823. doi: 10.1046/j.1523-1755.2003.00917.x

5. Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008; 73(4): 489-496. doi: 10.1038/sj.ki.5002708

6. Guttierrez OM, Farwell WR, Kermah D, Taylor EN. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination survey. Osteoporosis Int. 2011; 22(6): 1745-1753. doi: 10.1007/s00198-010-1383-2

7. Paik JM, Farwell WR, Taylor EN. Demographic, dietary, and serum factors and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int. 2012; 23(6): 1727-1736. doi: 10.1007/s00198-011-1776-x

8. Dall’era JE, Kim F, Chandhoke PS. Gender differences among hispanics and caucasians in symptomatic presentation of Kidney and Ureteral Stones. J Endourol. 2005; 19(3): 283-286. doi: 10.1089/end.2005.19.283

9. Mente A, Honey RJ, McLaughlin JR, Bull SB, Logan AG. Ethnic Differences in relative risk of idiopathic calcium nephrolithiasis in North America. J Urol. 2007; 178(5): 1992-1997. doi: 10.1016/j.juro.2007.07.024

10. Healy KA, Hubosky SG, Bagley DH. 24-hour urine collection in the metabolic evaluation of stone formers: Is one study adequate? J Endourol. 2013; 27(3): 374-378. doi: 10.1089/end.2012.0216

11. Pak CY, Peterson R, Poindexter JR. Adequacy of a single risk analysis in the medical evaluation of urolithiasis. J Urol. 2001; 165(2): 378-381. doi: 10.1097/00005392-200102000-00006

LATEST ARTICLES

Use of Black Soldier Fly (Hermetia illucens) Prepupae Reared on Organic Waste

review

2024 Mar

Isayas A. Kebede*, Haben F. Gebremeskel and Gelan D. Dahesa,
Figure 11. Risk Map for the Introduction of Ruminant Diseases at Borders

Original Research, peer reviewed

2024 Mar

Yassir Lezaar*, Mehdi Boumalik, Youssef Lhor, Moha El-Ayachi, Abelilah Araba and Mohammed Bouslikhane

Commentary, End-of-Life, Family Dynamics, palliative Care, peer reviewed

2024 Mar

Neil A. Nijhawan*, Rasha Mustafa and Aqeela Sheikh

Retrospective Study

2024 Mar

Shrenik J. Shah*, Abhishek Jha, Chirag Davara, Rushi Mistry and Kapil Kachhadiya

Attention, Disaster, Mindfulness, Original Research, peer reviewed

2024 Mar

Christina Hagen*, Lars Lien, Edvard Hauff and Trond Heir

review

2024 Mar

Isayas A. Kebede* and Gelan D. Dahesa

review

2024 Feb

Bekiyad S. Daro*; Yared A. Deneke, Jiregna G. Negasa and Ishetu N. Dibaba